Goldman Sachs has reduced Colgate-Palmolive India's price target to Rs 2,375.00 from Rs 2,630.00 following a disappointing Q4 performance. The company reported a 1.80% year-on-year revenue decline, affected by weak urban consumption and increased competition in oral care. Goldman Sachs maintains a 'sell' rating. Colgate-Palmolive expects challenges to persist through 1HFY26 but anticipates a rebound in 2HFY26. The company is focusing on premiumization strategies to navigate the current market conditions.
Colgate-Palmolive Expects EBITDA Margins to Stay in Low 30s Range May 22, 2025
Colgate-Palmolive Reports Sluggish Demand in Lower-Tier Urban Markets May 22, 2025
Colgate-Palmolive India: Q4 Profit and Revenue Miss Estimates, Declares Dividend May 21, 2025
Colgate-Palmolive India to Review Q4 Results on May 21 May 05, 2025